Astec Lifesciences' Q2 FY 2026-27 Quarterly Results

Result Summary

• Astec Lifesciences Ltd reported a 13.8% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Sep (Q2 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a decline of 2.9%.
• Its expenses for the quarter were up by 6.8% QoQ and 10.9% YoY.
• The net profit increased 99.9% QoQ and increased 53.2% YoY.
• The earnings per share (EPS) of Astec Lifesciences Ltd declined at 16.79 during Q2 FY 2026-27.

Financial Statments for Q2 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Astec Lifesciences Ltd operates within the agrochemical industry, primarily focusing on the production of active ingredients, intermediates, and formulations for crop protection. The company is known for its emphasis on research and development, aiming to innovate within the field of agricultural chemicals. As of the last known major developments, Astec Lifesciences has been focusing on expanding its product portfolio and enhancing its manufacturing capabilities to cater to both domestic and international markets. However, specific recent developments or changes in their strategic direction were not indicated in the provided data.

Revenue

In the second quarter of fiscal year 2027 (Q2FY27), Astec Lifesciences Ltd reported a total income of ₹72.64 crores, which reflects a decrease from ₹84.29 crores in the previous quarter (Q1FY27) and ₹74.84 crores in the same quarter of the previous fiscal year (Q2FY26). This represents a quarter-over-quarter (QoQ) decline of 13.8% and a year-over-year (YoY) decrease of 2.9%. The decline in total income suggests a challenging quarter for the company in terms of revenue generation when compared to both the previous quarter and the same period last year.

Profitability

The company's profitability metrics indicate a challenging quarter, with a Profit Before Tax (PBT) of -₹37.43 crores in Q2FY27. This is a significant increase in losses compared to -₹18.74 crores in Q1FY27 and -₹24.41 crores in Q2FY26. The QoQ change in PBT is 99.7%, while the YoY change is 53.3%. Profit After Tax (PAT) followed a similar pattern, with losses increasing to -₹37.40 crores from -₹18.71 crores in Q1FY27 and -₹24.42 crores in Q2FY26, showing a QoQ rise in losses of 99.9% and a YoY increase of 53.2%. The Earnings Per Share (EPS) also saw a corresponding decline, recorded at -₹16.79 compared to -₹8.40 in Q1FY27 and -₹11.34 in Q2FY26, marking a 99.9% QoQ increase in negative earnings and a 48.1% YoY increase.

Operating Metrics

Astec Lifesciences Ltd reported total expenses of ₹110.06 crores for Q2FY27, which is a 6.8% increase from ₹103.03 crores in Q1FY27 and a 10.9% increase from ₹99.25 crores in Q2FY26. The rise in total expenses amidst declining income could be attributed to various operational challenges or strategic investments, but specific reasons are not discernible from the provided data. The tax expense remained almost negligible at -₹0.03 crores, consistent with the previous quarter, but reflects a shift from a nominal tax income of ₹0.01 crores in Q2FY26. This consistency in tax treatment implies minimal impact on the overall financial performance from tax expenses during the quarter.